PROGNOSTIC VALUE OF RED CELL DISTRIBUTION WIDTH AT DIAGNOSIS (RDW) IN DIFFUSE LARGE B‐CELL LYMPHOMA

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rapid-growing form of non-Hodgkin lymphoma (NHL). The objective of this research was to assess the predictive role of lymphocyte to monocyte ratio (LMR), red cell distribution width (RDW) and neutrophil to lymphocyte ratio (NLR) values in the survival of DLBCL patients. A retrospective analysis of 136 DLBCL patients admitted to Nanakali Hospital for blood diseases and oncology from 2010-2020 was done. We assessed the correlation of LMR, RDW and NLR with patients’ characteristics and the impact on survival by the Kaplan–Meier method, the log-rank test, and Cox regression models for multivariate analysis. The complete remission rate was 61.7%, with a 5- year overall survival (OS) and progression-free survival (PFS) of 59.5% and 60%, respectively. The Log-rank test showed that LMR was significantly correlated with Ann Arbor staging (p= 0.040). There is a significant association between RDW and Eastern Cooperative Oncology Group performance status (ECOG-performance status) (p= 0.022), B symptoms (p= 0.026), Revised International prognostic index (R-IPI) (p= 0.004), lactate dehydrogenase (LDH) (p= 0.021), and beta 2 microglobulin (B2MG) (p= 0.007), whereas NLR had a significant correlation with LDH only (p=0.016). There were no significant differences in the 5-year OS or PFS in patients with different levels of RDW, LMR, and NLR. LMR, RDW and NLR were correlated with many of patients’ characteristics. However, none of the LMR, RDW and NLR did possess value to predict OS and PFS, and they cannot be used as biomarkers for survival evaluation of DLBCL.

Download Full-text

ABCL-064: Prognostic Value of Red Distribution Width (RDW) at Diagnosis in Diffuse Large B-Cell Lymphoma

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/s2152-2650(20)30867-3 ◽

2020 ◽

Vol 20 ◽

pp. S262

Author(s):

Eman M. Nagiub Abdelsalam ◽

Hanan Eltybe ◽

Ghada E.M. Abdallah ◽

Mostafa F. Mohammed Saleh

Keyword(s):

B Cell ◽

Prognostic Value ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Distribution Width ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients

The Scientific World JOURNAL ◽

10.1100/2012/897178 ◽

2012 ◽

Vol 2012 ◽

pp. 1-7 ◽

Cited By ~ 6

Author(s):

Ying Huang ◽

Sheng Ye ◽

Yabing Cao ◽

Zhiming Li ◽

Jiajia Huang ◽

...

Keyword(s):

B Cell ◽

Germinal Center ◽

Survival Data ◽

Prognostic Value ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Chinese Patients ◽

First Line ◽

Large B Cell Lymphoma ◽

Large B Cell

Diffuse large B-cell lymphoma (DLBCL) can be molecularly subtyped as either germinal center B-cell (GCB) or non-GCB. The role of rituximab(R) in these two groups remains unclear. We studied 204 patients with de novo DLBCL (107 treated with first-line CHOP; 97 treated with first-line R-CHOP), patients being stratified into GCB and non-GCB on the basis of BCL-6, CD10, and MUM1 protein expression. The relationships between clinical characteristics, survival data, and immunophenotype (IHC) were studied. The 5-year overall survival (OS) in the CHOP and R-CHOP groups was 50.4% and 66.6% (P=0.031), respectively. GCB patients had a better 5-year OS than non-GCB patients whether treated with CHOP or not (65.0% versus 40.9%;P=0.011). In contrast, there is no difference in the 5-year OS for the GCB and non-GCB with R-CHOP (76.5% versus 61.3%;P=0.141). In non-GCB subtype, additional rituximab improved survival better than CHOP (61.3% versus 40.9%;P=0.0303). These results indicated that addition of rituximab to standard chemotherapy eliminates the prognostic value of IHC-defined GCB and non-GCB phenotypes in DLBCL by improving the prognostic value of non-GCB subtype of DLBCL.

Download Full-text